Jazz Pharmaceuticals Bolsa (NASDAQ: JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ) Bolsa

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WAY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$40.00</td>
<td>$321.0K</td>
<td>257</td>
<td>3.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$157.50</td>
<td>$36.0K</td>
<td>5.3K</td>
<td>2.8K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$60.00</td>
<td>$25.0K</td>
<td>746</td>
<td>1.7K</td>
</tr>
<tr>
<td>PGEN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1.50</td>
<td>$35.0K</td>
<td>1.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>SMLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$45.00</td>
<td>$149.9K</td>
<td>270</td>
<td>864</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/01/25</td>
<td>$83.00</td>
<td>$25.0K</td>
<td>182</td>
<td>817</td>
</tr>
<tr>
<td>JAZZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$110.00</td>
<td>$165.3K</td>
<td>20</td>
<td>205</td>
</tr>
<tr>
<td>SMMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$36.0K</td>
<td>208</td>
<td>177</td>
</tr>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$28.00</td>
<td>$62.5K</td>
<td>114</td>
<td>100</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$260.00</td>
<td>$37.5K</td>
<td>2.7K</td>
<td>62</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For WAY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>), we notice a call option trade that happens to be bullish, expiring in 30 day(s) on August 15, 2025. This event was a transfer of 2293 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $321.0K, with a price of $140.0 per contract. There were 257 open contracts at this strike prior to today, and today 3002 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bullish sentiment. It expires in 2 day(s) on July 18, 2025. Parties traded 50 contract(s) at a $157.50 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $720.0 per contract. There were 5363 open contracts at this strike prior to today, and today 2820 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option trade with bearish sentiment. It expires in 9 day(s) on July 25, 2025. Parties traded 100 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $251.0 per contract. There were 746 open contracts at this strike prior to today, and today 1703 contract(s) were bought and sold. 
• Regarding PGEN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>), we observe a put option sweep with bearish sentiment. It expires in 93 day(s) on October 17, 2025. Parties traded 1000 contract(s) at a $1.50 strike. This particular put needed to be split into 32 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $35.0 per contract. There were 1470 open contracts at this strike prior to today, and today 1020 contract(s) were bought and sold. 
• Regarding SMLR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), we observe a call option trade with neutral sentiment. It expires in 156 day(s) on December 19, 2025. Parties traded 147 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $149.9K, with a price of $1020.0 per contract. There were 270 open contracts at this strike prior to today, and today 864 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on August 1, 2025. Parties traded 99 contract(s) at a $83.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $253.0 per contract. There were 182 open contracts at this strike prior to today, and today 817 contract(s) were bought and sold. 
• Regarding JAZZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), we observe a put option sweep with bullish sentiment. It expires in 93 day(s) on October 17, 2025. Parties traded 190 contract(s) at a $110.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $165.3K, with a price of $870.0 per contract. There were 20 open contracts at this strike prior to today, and today 205 contract(s) were bought and sold. 
• For SMMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), we notice a call option trade that happens to be bullish, expiring in 184 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $1800.0 per contract. There were 208 open contracts at this strike prior to today, and today 177 contract(s) were bought and sold. 
• For HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we notice a call option trade that happens to be bearish, expiring in 2 day(s) on July 18, 2025. This event was a transfer of 100 contract(s) at a $28.00 strike. The total cost received by the writing party (or parties) was $62.5K, with a price of $625.0 per contract. There were 114 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bullish, expiring in 184 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $1875.0 per contract. There were 2768 open contracts at this strike prior to today, and today 62 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

HROW

JAZZ

PGEN

SMLR

SMMT

10 Health Care Stocks Whale Activity In Today's Session

Jazz Pharmaceuticals&nbsp;plc (Nasdaq:&nbsp;JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company's next leader. This appointment reflects a key milestone in the Board's long-term succession planning process and previously disclosed CEO transition.
Ms. Gala was promoted to the role of President and COO in October 2023, after having served as Executive Vice President and Chief Financial Officer of the Company since March 2020. She brings more than 30 years of experience across finance, strategy, corporate development and commercialization. In her current role, she oversees the Company's global business operations, which include commercial, medical, research and development, technical operations and quality, as well as corporate strategy. Ms. Gala has played a critical role in driving Jazz's ongoing transformation, including&nbsp;architecting a business development strategy that has diversified the Company's portfolio, driven total revenue growth of nearly 90%, built broad capabilities, and established a pipeline that has positioned the Company for value creation and sustainable growth.
"The Board conducted a thorough and thoughtful search including both internal and external candidates, and we're highly confident that Renee is exactly the right leader to build on Jazz's momentum," said Rick Winningham, Lead Independent Director. "The Board's priority was to find an exceptional leader who could not only operate the business but also serve as a catalyst in driving long-term growth at this important moment for the Company. Among a field of highly capable and qualified candidates, Renee was the clear standout, with a compelling set of experiences and skillsets, as well as a strong track record of driving high performance and change at Jazz through both corporate development and operational initiatives. The Board has a strong focus on Jazz's evolution and delivering value, and we believe Renee is ideally equipped to drive and deliver Jazz's continued success."
"I am honored to step into the CEO role and build upon Jazz's extraordinary legacy, fueled by exceptional people, a spirit of purpose and an unwavering commitment to patients," said Ms. Gala. "With a market-leading portfolio of medicines, a promising pipeline, a strong financial position and an ongoing focus on corporate development, Jazz has immense potential—and more work to be done to realize it. I look forward to continuing the important efforts underway and working with our team to pursue new opportunities—both within our portfolio and through external innovation—to drive greater value for our patients and shareholders. I want to express my deep appreciation to Bruce for his steadfast leadership over the past two decades in building an organization defined by patient-centricity and mutual respect, a foundation that will serve us well into the future. I'm grateful for the opportunity to have partnered with Bruce over the last five years and look forward to continuing to work with him and the Board in this next chapter."
"I co-founded Jazz 22 years ago and am immensely proud of our journey. From the beginning, our mission has been to work tirelessly to transform patient lives," said Mr.&nbsp;Cozadd. "We have since grown into an innovative biopharma company with expanded commercial and scientific capabilities to drive the next phase of our evolution, and a value rich pipeline poised to reach even more patients than we ever thought possible. I am thrilled to be handing over the reins to Renee and am excited for her to lead Jazz into our next phase of growth. In her role as Jazz's CFO and then as our President and COO, Renee's leadership has been critical in Jazz's transformation into a high-growth biopharmaceutical company fueled by a strong R&amp;D pipeline and robust commercial operations. I am confident that she will continue to further this mission as CEO, while nurturing the culture that makes Jazz such a compelling place to spend your career."
Mr.&nbsp;Cozadd will continue to serve as Chairperson of the Board, providing strategic input as the Company continues to execute on its growth strategy.

News

Management

Jazz Pharma Names Renee Gala as New CEO; Co-Founder Bruce Cozadd to Stay On as Chair

Avadel Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) is under fire from its shareholder ASL Strategic Value Fund, LP, which is pushing for a complete overhaul of the board following what it describes as a series of strategic failures tied to Lumryz, the company&#8217;s <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">once-nightly narcolepsy treatment</a>.
In a letter released Monday, ASL argued Avadel failed to capitalize on Lumryz&#8217;s market potential, costing the company hundreds of millions in revenue and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46164920/asl-strategic-value-fund-issues-open-letter-to-avadel-shareholders" rel="noreferrer noopener">diminishing shareholder value</a>.
ASL, which holds approximately $15 million in Avadel stock, criticized the company&#8217;s slow patient conversion from Jazz Pharmaceutical Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Xyrem to Lumryz, despite the latter having been deemed &#8220;clinically superior&#8221; by the FDA.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42891870/avadel-pharmaceuticals-misses-earnings-estimate-but-posts-150-increase-in-sales-from-its-narcolepsy-drug-lumryz" rel="noreferrer noopener">Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ</a>
Since Lumryz&#8217;s approval in 2021, only about 1,000 patients have made the switch, which ASL estimates represents a $600 million to $800 million shortfall.
The group called this delay in targeting Xyrem patients a &#8220;strategic blunder,&#8221; claiming it has shaved $5 to $7 per share from shareholder value.
The fund is urging shareholders to vote out the current board at the July 29 annual meeting. It is pressing Avadel to engage an investment bank to evaluate options for monetizing Lumryz.
This includes exploring partnerships or licensing deals, particularly given its recent Orphan Drug Designation for idiopathic hypersomnia (IH), a move that could generate an additional $500 million to $1 billion in annual revenue if Lumryz is approved for the rare sleep disorder.
Avadel defended its strategy, saying it is actively working with major shareholders and remains committed to unlocking Lumryz&#8217;s full value.
The company also highlighted a recent legal win in which a U.S. court affirmed the FDA&#8217;s conclusion that Lumryz&#8217;s once-nightly dosing is clinically superior to its competitors. However, ASL pointed to ongoing litigation with Jazz Pharmaceuticals, six lawsuits in total, as another area where the board has underdelivered.
With one case heading to trial within four months and over $1 billion at stake, ASL accuses leadership of failing to act urgently or communicate the opportunity to investors.
Beyond strategic concerns, ASL cited governance issues, including uncounted shareholder votes and a lack of transparency around executive pay.
Despite Avadel&#8217;s falling market capitalization, from $2.5 billion to $900 million over two years, CEO compensation was $7.4 million in 2024, raising further concerns over accountability.
On Friday, Avadel Pharmaceuticals said the U.S. Court of Appeals for the D.C. Circuit upheld a lower court&#8217;s decision siding with the U.S. Food and Drug Administration (FDA) in a case <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46164897/avadel-pharmaceuticals-announces-unanimous-appeals-court-decision-upholding-fda-approval-of-lumryz" rel="noreferrer noopener">brought by Jazz Pharmaceuticals</a>.
Earlier in June, the FDA granted Orphan Drug Designation to Lumryz for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45789373/avadel-pharmaceuticals-receives-orphan-drug-designation-from-fda-for-lumryz-sodium-oxybate-for-ext" rel="noreferrer noopener">Idiopathic Hypersomnia</a>.
Price Action: AVDL stock is trading lower by 0.40% to $8.83 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46199715/warner-bros-discovery-wbd-stock-slides-on-major-stake-sale" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery (WBD) Stock Slides On Major Stake Sale</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Biotech

Health Care

General

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz

– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial –
DUBLIN, July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that the European Commission (EC) has granted conditional marketing authorization1&nbsp;for Ziihera&#xAE; (zanidatamab), a dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)†&nbsp;biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.2
BTCs, which include gallbladder cancer (GBC) and cholangiocarcinoma (CCA), are a rare and aggressive group of cancers,3 with most cases diagnosed at an advanced stage4 when curative surgery is no longer an option.5,6,7 Globally, approximately 26% of patients with BTC are HER2-positive,8 a biomarker associated with poorer outcomes compared to HER2-negative disease.9
Ziihera&nbsp;is the first HER2-targeted therapy given conditional authorization for HER2-positive BTC in the European Union (EU). Continued approval for this indication is contingent upon verification and description of clinical benefit in the ongoing Phase 3 HERIZON-BTC-302 trial, which is evaluating zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.10

Global

Jazz Pharmaceuticals Receives Conditional EU Approval For Ziihera To Treat HER2-Positive Biliary Tract Cancer Based On Phase 2b Trial

As previously disclosed, on June&nbsp;22, 2023, Jazz Pharmaceuticals,&nbsp;Inc. ("Jazz") filed an Administrative Procedure Act ("APA") suit against the U.S. Food and Drug Administration (the "FDA"), the U.S. Department of Health and Human Services, the Secretary of Health and Human Services and the Commissioner of Food and Drugs in the United States District Court for the District of Columbia (the "D.C. Court") related to the New Drug Application for LUMRYZ. This suit alleged that the FDA's approval of LUMRYZ was an unlawful agency action and asked the D.C. Court to set aside FDA's approval of LUMRYZ.
&nbsp;
On October&nbsp;30, 2024, the D.C. Court granted the FDA and Avadel Pharmaceuticals plc's Motions for Summary Judgment with respect to the sole count in Jazz's complaint and denied Jazz's Motion for Summary Judgment regarding the same. On November&nbsp;15, 2024, Jazz filed a notice of appeal to the United States Court of Appeals for the District of Columbia Circuit (the "D.C. Court of Appeals") concerning the D.C. Court's October&nbsp;30, 2024 ruling.
&nbsp;
On June&nbsp;27, 2025, the D.C. Court of Appeals, in a unanimous decision, affirmed the D.C. Court's ruling and upheld the FDA's approval of LUMRYZ.

Legal

Avadel Pharmaceuticals Announces Appeals Court Unanimously Upholds FDA Approval Of LUMRYZ

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $202 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target

Target Action (PDUFA) Date set for October 7, 2025
Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance setting
Jazz to host investor webcast on Tuesday, June 10 at 4:30 p.m. EDT / 9:30 p.m. IST to review Zepzelca data
For U.S. media and investors only
DUBLIN, June 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Zepzelca&#xAE; (lurbinectedin) in combination with atezolizumab (Tecentriq&#xAE;) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC)&nbsp;whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin, and etoposide for Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of October 7, 2025. Priority Review is granted to applications for drugs that have the potential to significantly improve the treatment, prevention, or diagnosis of serious conditions.&nbsp;

FDA Accepts Jazz Pharma's sNDA For Zepzelca In Combination With Atezolizumab As First-Line Maintenance Treatment For People With ES-SCLC For Priority Review, With PDUFA Action Date Of October 7, 2025

Jazz Pharmaceuticals Reveals Phase 4 Data Evaluating Treatment Benefits Of Xywav Oral Solution In People With Narcolepsy At SLEEP 2025

Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) on Monday revealed results from the Phase 3 IMforte study of Zepzelca (lurbinectedin) in combination with Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Tecentriq (atezolizumab) as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">etoposide and atezolizumab</a>.
The study met both primary endpoints, demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to atezolizumab alone, <a href="https://www.benzinga.com/pressreleases/25/06/n45733928/jazz-pharmaceuticals-announces-zepzelca-lurbinectedin-and-atezolizumab-tecentriq-combination-signi">according to a press release</a>. 
IMforte is the first global Phase 3 trial to demonstrate clinically meaningful PFS and OS benefits in the first-line maintenance setting for ES-SCLC. It supports maintenance therapy with&nbsp;Zepzelca plus atezolizumab as a new standard of care for patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44140310/jazz-pharma-to-buy-chimerix-for-935-million-strengthening-rare-cancer-pipeline" rel="noreferrer noopener">Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline</a>
The data were presented at the 2025 American Society of Clinical Oncology Annual Meeting.
Following induction therapy with carboplatin, etoposide and atezolizumab, patients who did not have disease progression were randomized to receive&nbsp;Zepzelca&nbsp;plus atezolizumab or atezolizumab alone.
Four hundred and eighty-three patients were randomized after completion of four cycles of induction therapy with atezolizumab plus carboplatin and etoposide.
From the point of randomization, the median PFS was 5.4 months for the&nbsp;Zepzelca&nbsp;plus atezolizumab combination versus 2.1 months for atezolizumab alone, and the median OS was 13.2 months versus 10.6 months.
Compared to atezolizumab alone, the combination reduced the risk of disease progression or death by 46% and the risk of death by 27%. The&nbsp;Zepzelca&nbsp;plus atezolizumab combination had no new or unexpected safety signals.
The&nbsp;Zepzelca&nbsp;plus atezolizumab&nbsp;combination as maintenance therapy was generally well tolerated, and no new safety signals were identified.
In the&nbsp;Zepzelca&nbsp;plus atezolizumab&nbsp;and atezolizumab arms, respectively, treatment-related adverse events (TRAEs) occurred in 83.5% versus 40.0% of patients, with Grade 3-4 TRAEs in 25.6% versus 5.8% and Grade 5 TRAEs in 0.8% (two patients with sepsis and febrile neutropenia) versus 0.4% (one patient with sepsis).
AEs led to treatment discontinuation in 6.2% of patients in the Zepzecla plus atezolizumab&nbsp;arm and 3.3% in the atezolizumab arm.
JAZZ Price Action: JAZZ stock is up 2.07% at $110.53 at publication on Tuesday.
Read Next:
 • <a href="https://www.benzinga.com/markets/earnings/25/06/45746307/dollar-general-boosts-annual-outlook-despite-ongoing-tariff-uncertainty" target="_blank" rel="noreferrer noopener">Dollar General Boosts Annual Outlook Despite Ongoing Tariff Uncertainty</a>
Photo: Shutterstock

RHHBY

Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $187.36, a high estimate of $230.00, and a low estimate of $147.00. Observing a 0.05% increase, the current average has risen from the previous average price target of $187.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1748952029_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Jazz Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$172.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$183.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$179.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Gregory Fraser</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Jazz Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Jazz Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Jazz Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>Discovering Jazz Pharmaceuticals: A Closer Look</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Jazz Pharmaceuticals faced challenges, resulting in a decline of approximately -0.46% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.24%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.79%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below the industry average at 1.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts

First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months&nbsp;for atezolizumab alone from the point of randomization
First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance
Results presented at the ASCO 2025 Annual Meeting and simultaneously published in The Lancet
Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data
For U.S. media and investors only
DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced positive results from the Phase 3 IMforte study of Zepzelca&#xAE; (lurbinectedin) in combination with atezolizumab (Tecentriq&#xAE;) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and atezolizumab. The study met both primary endpoints, demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to atezolizumab alone.
IMforte is the first global Phase 3 trial to demonstrate clinically meaningful PFS and OS benefits in the first-line maintenance setting for ES-SCLC and supports maintenance therapy with Zepzelca&nbsp;plus atezolizumab as a new standard of care for patients. The data were presented today in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published simultaneously in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439716-1&amp;h=26984983&amp;u=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736(25)01011-6%2Ffulltext&amp;a=The+Lancet">The Lancet</a>. Data from the trial served as the basis for the supplemental New Drug Application (sNDA) submission to the U.S. Food and Drug Administration&nbsp;(FDA).
Following induction therapy with carboplatin, etoposide and atezolizumab, patients who did not have disease progression were randomized to receive Zepzelca plus atezolizumab or atezolizumab alone. From the point of randomization, the median PFS was 5.4 months for the Zepzelca plus atezolizumab combination versus 2.1 months for atezolizumab alone (stratified HR = 0.54, 95% CI: 0.43–0.67; p &lt; 0.0001), and median OS was 13.2 months versus 10.6 months (stratified hazard ratio [HR] = 0.73; 95% CI: 0.57–0.95; p = 0.0174). The combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared to atezolizumab alone. The Zepzelca plus atezolizumab combination had no new or unexpected safety signals.

Jazz Pharmaceuticals Announces Phase 3 IMforte Trial Results Showing Zepzelca Plus Atezolizumab First-Line Maintenance Therapy Reduces Disease Progression Risk By 46% And Extends Median Overall Survival To 13.2 Months In ES-SCLC; Data Presented At ASCO 2025 And Published In The Lancet, Supporting New Standard Of Care And FDA sNDA Submission

Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile
Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology
For U.S. media and investors only&nbsp;
DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial evaluating Ziihera&#xAE; (zanidatamab-hrii), a dual HER2-targeted bispecific antibody, in combination with chemotherapy for the investigational use in first-line HER2-positive (IHC 3+ or IHC 2+/FISH+) locally advanced nonresectable gastroesophageal adenocarcinoma (mGEA). The data were featured as a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439717-1&amp;h=49472503&amp;u=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045(25)00287-6%2Ffulltext&amp;a=The+Lancet+Oncology">The Lancet Oncology</a>.
Among 41 patients with centrally confirmed HER2-positive tumors, treatment with Ziihera in combination with physician's choice of chemotherapy resulted in a median progression-free survival (PFS) of 15.2 months [95% CI: 9.5, 33.4], and a median overall survival (OS) of 36.5 months [95% CI: 23.6, not estimable (NE)]. Median PFS remained stable with the additional four-year follow-up, consistent with previously reported results.
Among all 46 patients in the study with HER2-expressing mGEA, median PFS was 12.5 months [95% CI: 8.2, 21.8], and median OS also reached 36.5 months [95% CI: 23.6, NE], with the longest observed survival at 57.9 months (censored at data cutoff). Long-term follow-up also demonstrated low discontinuation rates, with no new safety signals observed.

Jazz Pharmaceuticals Reports Long-Term Phase 2 Data For Ziihera Showing 36.5-Month Median Overall Survival And Durable Responses In HER2-Positive Gastroesophageal Cancer, With Manageable Safety Profile; Results Presented At ASCO 2025 And Published In The Lancet Oncology

In a recent SEC filing, it was revealed that Seamus Mulligan, Board Member at Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), made a noteworthy insider purchase on May 13,.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001232524/000176558125000042//Archives/edgar/data/1232524/000176558125000042/0001765581-25-000042-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday unveiled that Mulligan made a notable purchase of 101,621 shares of Jazz Pharmaceuticals, valuing at $9,993,081.
The latest market snapshot at Wednesday morning reveals Jazz Pharmaceuticals shares up by 0.98%, trading at $103.92.
<h3>Unveiling the Story Behind Jazz Pharmaceuticals</h3>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Key Indicators: Jazz Pharmaceuticals's Financial Health</h3>
Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -0.46%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: With a high gross margin of 88.35%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Jazz Pharmaceuticals's EPS is below the industry average. The company faced challenges with a current EPS of -1.52. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 1.3. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 13.98 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 1.66 is lower than the industry average, implying a discounted valuation for Jazz Pharmaceuticals's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 7.36 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001232524">Check Out The Full List Of Jazz Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Major Purchase Alert: Seamus Mulligan Invests $9.99M In Jazz Pharmaceuticals Stock

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and lowers the price target from $167 to $155.

Baird Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $155

RBC Capital analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and lowers the price target from $182 to $172.

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172

WIIM

Jazz Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 adjusted EPS guidance. Also, Piper Sandler and Morgan Stanley lowered their respective price targets on the stock.

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $176 to $147.

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Lowers Price Target to $147

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $183 to $166.

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $166

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $200 price target.

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target

Press Releases

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

Earnings

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Jazz Pharmaceuticals

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL